• In February 2026, MoonLake Immunotherapeutics reported full-year 2025 results showing a net loss of US$227.32 million, compared with US$118.94 million in 2024, and a basic loss per share from continuing operations of US$3.53 versus US$1.89.
• The widening loss underscores how the company’s spending and financial profile evolved over the year, sharpening investor focus on its path toward more sustainable economics.
• With the company’s recent share price gains, we’ll examine how the sharply higher annual net loss shapes MoonLake’s broader investment narrative.

Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

What Is MoonLake Immunotherapeutics’ Investment Narrative?

To own MoonLake Immunotherapeutics,…